{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T15:50:08Z","timestamp":1789919408950,"version":"4.0.1"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,4,10]],"date-time":"2020-04-10T00:00:00Z","timestamp":1586476800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,4,10]],"date-time":"2020-04-10T00:00:00Z","timestamp":1586476800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Tuberculosis (TB) disease is a common opportunistic infection among people living with HIV (PLHIV). WHO recommends at least 6 months of isoniazid Preventive Therapy (IPT) to reduce the risk of active TB. It is important to monitor the six-month IPT completion since a suboptimal dose may not protect PLHIV from TB infection. This study determined the six-month IPT completion and factors associated with six-month IPT completion among PLHIV aged 15\u2009years or more in Dar es Salaam region, Tanzania.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Secondary analysis of routine data from PLHIV attending 58 care and treatment clinics in Dar es Salaam region was used. PLHIV, aged 15\u2009years and above, who screened negative for TB symptoms and initiated IPT from January, 2013 to June, 2017 were recruited. Modified Poisson regression with robust standard errors was used to estimate prevalence ratios (PR) and 95% confidence interval (CI) for factors associated with IPT completion. Multilevel analysis was used to account for health facility random effects in order to estimate adjusted PR (APR) for factors associated with IPT six-month completion.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 29,382 PLHIV were initiated IPT, with 21,808 (74%) female. Overall 17,092 (58%) six-month IPT completion, increasing from 42% (773\/1857) in year 2013 to 76% (2929\/3856) in 2017. Multilevel multivariable model accounting for health facilities as clusters, showed PLHIV who were not on ART had 46% lower IPT completion compared to those were on ART (APR: 0.54: 95%CI: 0.45\u20130.64). There was 37% lower IPT completion among PLHIV who transferred from another clinic (APR: 0.63: 95% CI (0.54\u20130.74) compared to those who did not transfer. PLHIV aged 25\u201334\u2009years had a 6% lower prevalence of IPT completion as compared to those aged 15 to 24\u2009years (APR:0.94 95%CI:0.89\u20130.98).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The IPT completion rate in PLHIV increased over time, but there was lower IPT completion in PLHIV who transferred from other clinics, who were aged 25 to 34\u2009years and those not on ART. Interventions to support IPT in these groups are urgently needed.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12879-020-04997-6","type":"journal-article","created":{"date-parts":[[2020,4,10]],"date-time":"2020-04-10T07:02:18Z","timestamp":1586502138000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Determinants of isoniazid preventive therapy completion among people living with HIV attending care and treatment clinics from 2013 to 2017 in Dar es Salaam Region, Tanzania. A cross-sectional analytical study"],"prefix":"10.1186","volume":"20","author":[{"given":"Masanja","family":"Robert","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jim","family":"Todd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard J.","family":"Ngowi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sia E.","family":"Msuya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angella","family":"Ramadhani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veryhel","family":"Sambu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isaya","family":"Jerry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin R.","family":"Mujuni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Mahande","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James S.","family":"Ngocho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Werner","family":"Maokola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,4,10]]},"reference":[{"key":"4997_CR1","unstructured":"WHO UNICEF and UNAIDS. A Guide on Indicators for Monitoring and Reporting on the Health Sector Response to HIV \/ AIDS [Internet]. 2011. Available from: http:\/\/www.who.int\/hiv\/pub\/2010progressreport\/report\/en\/."},{"key":"4997_CR2","unstructured":"WHO. The global Tuberculosis report. [Internet]. 2014. Available from: http:\/\/www.who.int\/tb\/publications."},{"key":"4997_CR3","doi-asserted-by":"crossref","unstructured":"Getachew Y, Mekonnen W. Correlates of adherence and utilization of isoniazid preventive therapy in HIV patients. Res Artic Infect Dis [Internet] 2015;5(2):45\u201350. Available from: www.jmidonline.org.","DOI":"10.5799\/ahinjs.02.2015.02.0175"},{"key":"4997_CR4","unstructured":"MOHCDGEC. National Guidelines for Management of HIV and AIDS Updated 11July 2017 to incoprporate BAKITA &CDC 11.07.2017. Dar es Salaam; 2017."},{"key":"4997_CR5","unstructured":"MOHCDGEC. National opperational guideline for community based TB, TB\/HIV and DR-TB interventions. Dar es Salaam: NTLP; 2016."},{"issue":"9","key":"4997_CR6","first-page":"1037","volume":"12","author":"PJ Munseri","year":"2008","unstructured":"Munseri PJ, Talbot EA, Mtei L, von Reyn CF. Completion of isoniazid preventive therapy among HIV-infected patients in Tanzania. Int J Tuberc Lung Dis. 2008;12(9):1037\u201341.","journal-title":"Int J Tuberc Lung Dis"},{"key":"4997_CR7","unstructured":"WHO. Global tuberculosis Report 2017 [Internet]. 2017. Available from: http:\/\/www.who.int\/tb\/publications."},{"key":"4997_CR8","doi-asserted-by":"crossref","unstructured":"Floyd K, Glaziou P, Zumla A, Raviglione M. The global tuberculosis epidemic and progress in care, prevention, and research: an overview in year 3 of the End TB era. Lancet Respir Med 2018. 2018;6:299\u2013314.","DOI":"10.1016\/S2213-2600(18)30057-2"},{"key":"4997_CR9","doi-asserted-by":"crossref","unstructured":"Gunda DW, Maganga SC, Nkandala I, Kilonzo SB, Mpondo BC, Shao ER, et al. Prevalence and risk factors of active TB among adult HIV patients receiving ART in northwestern Tanzania: a retrospective cohort study. 2018;.","DOI":"10.1155\/2018\/1346104"},{"key":"4997_CR10","unstructured":"WHO. Global Tuberculosis Report; World Health Orgarnization (WHO) [Internet]. 2018. Available from: http:\/\/www.who.int\/tb\/joint-initiative\/en\/."},{"key":"4997_CR11","unstructured":"NTLLP. Kenya National Strategic Plan on Tuberculosis, Leprosy and Lung Health 2015\u20132018 [Internet]. 2014. Available from: http:\/\/healthservices.uonbi.ac.ke\/sites\/default\/files\/centraladmin\/healthservices\/Kenya National Strategic Plan on Tuberculosis, Leprosy.pdf."},{"key":"4997_CR12","unstructured":"WHO. Use of high burden country lists for TB by WHO in the post-2015 era [Internet]. Geneva; 2015. Available from: http:\/\/whqlibdoc.who.int\/hq\/1998\/WHO_TB_98.245.pdf?ua."},{"key":"4997_CR13","unstructured":"COP. Country operational plan (COP) strategic direction summary. 2016."},{"key":"4997_CR14","unstructured":"NTLP. National tuberculosis and leprosy programe in Tanzania [internet]. Dar Es Salaam; 2006. Available from: www.ntlp.go.tz."},{"key":"4997_CR15","doi-asserted-by":"crossref","unstructured":"Maokola W, Ngowi B, Lawson L, Mahande M, Todd J, Msuya S. Performance of and factors associated with TB screening and diagnosis using Sputum microscopy examination among People Living with HIV: analysis of 2012\u20132016 routine HIV data in Tanzania. Front Public Heal. 2020;7(404).","DOI":"10.3389\/fpubh.2019.00404"},{"key":"4997_CR16","doi-asserted-by":"crossref","unstructured":"Zhao Y, Li M, Yuan S. Analysis of Transmission and Control of Tuberculosis in Mainland China, 2005\u20132016, Based on the Age-Structure Mathematical Model. Int J Environ Res Public Health. 2016:535\u20139.","DOI":"10.3390\/ijerph14101192"},{"key":"4997_CR17","unstructured":"CDC. Isoniazid (INH) for the Treatment of TB Infection NOTE: United State of America, Califonia; 2017. p. 1\u20132."},{"key":"4997_CR18","unstructured":"Kahwati LC, Feltner C, Halpern M, Woodell CL, Boland E, Amick HR, et al. Screening for Latent Tuberculosis Infection in Adults: An Evidence Review for the U.S. Preventive Services Task Force. Agency Healthc Res Qual. 2016;142(14\u201305212-EF-1 September)."},{"key":"4997_CR19","doi-asserted-by":"crossref","unstructured":"Ayele AA, Atnafie SA, Balcha DD, Weredekal AT, Woldegiorgis BA, Wotte MM, et al. Self-reported adherence and associated factors to isoniazid preventive therapy for latent tuberculosis among people living with HIV\/AIDS at health centers in Gondar town. North West Ethiop. 2017:743\u20139.","DOI":"10.2147\/PPA.S131314"},{"key":"4997_CR20","doi-asserted-by":"crossref","unstructured":"Sabasaba A, Mwambi H, Somi G, Ramadhani A, Mahande J M. Effect of isoniazid preventive therapy on tuberculosis incidence and associated risk factors among HIV infected adults in Tanzania:a retrospective cohort study. BMC Infect Dis. 2019;2019:19\u201362. Available from: https:\/\/doi.org\/10.1186\/s12879-019-3696-x%0A(2019).","DOI":"10.1186\/s12879-019-3696-x"},{"key":"4997_CR21","doi-asserted-by":"crossref","unstructured":"Getahuna H, Granichb R, Sculiera D, Gunneberga C, Blanca L, Nunna P, et al. Implementation of isoniazid preventive therapy for people living with HIV worldwide: barriers and solutions. AIDS. 2010;24 (suppl(2010):S57\u2013S65. Available from: ISSN 0269\u20139370 Q 2010 Wolters Kluwer Health %7C Lippincott Williams & Wilkins Copyright \u00a9 Lippincott Williams & Wilkins.","DOI":"10.1097\/01.aids.0000391023.03037.1f"},{"key":"4997_CR22","doi-asserted-by":"crossref","unstructured":"Granich R, Akolo C, Gunneberg C, Getahun H, Williams P, Williams B. Prevention of tuberculosis in people living with HIV [internet]. Geneva: Clinical Infectious Diseases; 2010. Available from: http:\/\/cid.oxfordjournals.org\/.","DOI":"10.1086\/651494"},{"key":"4997_CR23","unstructured":"Falzon D, Getahun H, Kanchar A, Mirzayev F, Raviglione M, Timimi H, et al.. Use of high burden country lists for TB by WHO in the post-2015 era. 2015;(April)."},{"key":"4997_CR24","doi-asserted-by":"crossref","unstructured":"Alsdurf H, Hill PC, Matteelli A, Getahun H, Menzies D. The cascade of care in diagnosis and treatment of latent tuberculosis infection: a systematic review and meta-analysis. 2016;16(30216\u2013X):S1473\u20133099.","DOI":"10.1016\/S1473-3099(16)30216-X"},{"key":"4997_CR25","unstructured":"Hart L, Hamilton C, Boocher K. Isoniazid preventive therapy for the prevention of tuberculosis in people living with HIV \/ AIDS providing isoniazid to. 2011."},{"key":"4997_CR26","doi-asserted-by":"crossref","unstructured":"Samandari T, Agizew TB, Nyirenda S, Tedla Z, Sibanda T, Mosimaneotsile B, et al. Tuberculosis incidence after 36 months\u2019 isoniazid prophylaxis in HIV-infected adults in Botswana: a posttrial observational analysis. PMC 2016 December 01. 2015;28; 29(3): 351\u2013359.","DOI":"10.1097\/QAD.0000000000000535"},{"issue":"15","key":"4997_CR27","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1186\/s12879-015-1089-3","volume":"2015","author":"HT Ayele","year":"2015","unstructured":"Ayele HT, van Mourik MS, Bonten MJ. Effect of isoniazid preventive therapy on tuberculosis or death in persons with HIV: a retrospective cohort study. BMC Infect Dis. 2015;2015(15):334.","journal-title":"BMC Infect Dis"},{"key":"4997_CR28","doi-asserted-by":"crossref","unstructured":"Al-Darraji HAA, Kamarulzaman A, Altice FL. Isoniazid preventive therapy in correctional facilities: a systematic review. Int J Tuberc Lung Dis 2012;16(7):871\u2013879. Available from: http:\/\/dx.doi.org\/10.5588\/ijtld.11.0447.","DOI":"10.5588\/ijtld.11.0447"},{"key":"4997_CR29","doi-asserted-by":"crossref","unstructured":"Ousley J, Soe KP, Kyaw NTT, Anicete R, Mon PE, Lwin H, et al. IPT during HIV treatment in Myanmar: high rates of coverage, completion and drug adherence. Public Heal Action. 2018;8(1).","DOI":"10.5588\/pha.17.0087"},{"issue":"Suppl 5","key":"4997_CR30","first-page":"S49","volume":"24","author":"I Giselle","year":"2010","unstructured":"Giselle I, Bonnie SK, Cohne S, Efron A, Antonio GP, Lawrence HM, et al. The implementation of isoniazid preventive therapy in HIV clinics: the experience from the TB\/HIV in Rio (THRio) study. NIH Public Access. 2010;24(Suppl 5):S49\u201356.","journal-title":"NIH Public Access"},{"issue":"9","key":"4997_CR31","first-page":"1","volume":"2019","author":"GP Dhungana","year":"2019","unstructured":"Dhungana GP, Thekkur P, Chinnakali P, Bhatta U, Pandey B, Zhang W-H. Open access research initiation and completion rates of isoniazid preventive therapy among people living with HIV in far-Western region of Nepal: a retrospective cohort study. BMJ Open Access. 2019;2019(9):1\u20139.","journal-title":"BMJ Open Access"},{"key":"4997_CR32","doi-asserted-by":"crossref","unstructured":"Takarinda KC, Choto RC, Harries AD, Mutasa-Apollo T, Chakanyuka-Musanhu C. Routine implementation of isoniazid preventive therapy in HIV-infected patients in seven pilot sites in Zimbabwe. Public Heal Action [Internet]. 2017; Available from: www.theunion.org.","DOI":"10.5588\/pha.16.0102"},{"key":"4997_CR33","doi-asserted-by":"crossref","unstructured":"Maharaj B, Gengiah TN, Nonhlanhla Y-Z, Gengiah S, Naidoo A, Naidoo K. Implementing Isoniazid Preventive Therapy in a TB-treatment experienced cohort on ART. Vol. 4. 2017.","DOI":"10.5588\/ijtld.16.0775"},{"key":"4997_CR34","doi-asserted-by":"crossref","unstructured":"Oni T, Tsekela R, Kwaza B, Manjezi L, Bangani N, Wilkinson KA, et al. A Recent HIV Diagnosis Is Associated with Non- Completion of Isoniazid Preventive Therapy in an HIV- Infected Cohort in Cape Town. PLoS One. 2012;7(12):e52489. Available from: www.plosone.org.","DOI":"10.1371\/journal.pone.0052489"},{"key":"4997_CR35","doi-asserted-by":"crossref","unstructured":"Yotebieng M, Edmonds A, Lelo P, Wenzi LK, Bu PTN-, Lusiama J, et al. High completion of isoniazid preventive therapy among HIV-infected children and adults in Kinshasa, Democratic Republic of Congo. Res Lett AIDS 2015. 2015;29:2055\u20132060.","DOI":"10.1097\/QAD.0000000000000791"},{"key":"4997_CR36","doi-asserted-by":"crossref","unstructured":"Tram KH, Mwangwa F, Atukunda M, Owaraganise A, Ayieko J, Plenty A, et al. Isoniazid Preventive Therapy Completion in the Era of Differentiated HIV Care. J Acquir Immune Defic Syndr. 2017;76(5). Available from: Copyright \u00a9 2017 The author(s). Published by Wolters Kluwer Health, Inc. www.jaids.com.","DOI":"10.1097\/QAI.0000000000001540"},{"key":"4997_CR37","unstructured":"LaCourse M S, Graham M S, Jacko W, Deya W R, Masese N L, Mandaliya N K, et al. Evaluation of the isoniazid preventive therapy care Casecade among HIV-positive female sex Workers in Mombasa, Kenya. JAIDS J Acquir Immune Defic Syndr Publ Ahead Print DOI 2014;."},{"key":"4997_CR38","doi-asserted-by":"crossref","unstructured":"Shayo GA, Moshiro C, Aboud S, Bakari M, Mugusi FM. Acceptability and adherence to Isoniazid preventive therapy in HIV-infected patients clinically screened for latent tuberculosis in Dar es Salaam, Tanzania. BMC Infect Dis. 2015;2015(15):368. Available from: www.biomedcentral.com\/submit.","DOI":"10.1186\/s12879-015-1085-7"},{"issue":"11","key":"4997_CR39","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.5588\/ijtld.10.0788","volume":"15","author":"C Kabali","year":"2011","unstructured":"Kabali C, von Reyn CF, Brooks DR, Waddell R, Mtei L, Bakari M, et al. Completion of isoniazid preventive therapy and survival in HIV-infected, TST-positive adults in Tanzania. Int J Tuberc Lung Dis. 2011;15(11):1515\u201321.","journal-title":"Int J Tuberc Lung Dis"},{"key":"4997_CR40","unstructured":"Bakari M, Sandstrom E, Mhalu F, Pallangyo K. Isoniazid prophylaxis for tuberculosis prevention among HIV infected police officers in Dar Es Salaam. East Africa Med J. 2000."},{"key":"4997_CR41","doi-asserted-by":"crossref","unstructured":"Glaziou P, Floyd K, Sismanidis C, Raviglione M. Global Epidemiology of Tuberculosis. Cold Spring Harb Perspect Med [Internet]. 2015; Available from: www.who.int\/tb\/data.","DOI":"10.1093\/med\/9780190220891.003.0005"},{"key":"4997_CR42","unstructured":"WHO. Guidelines for managing advanced HIV disease and rapid initiation of antiretroviral therapy. Behav Inf Technol. 2017 Apr 7;2(2):127\u2013161. Available from: http:\/\/apps.who.int\/iris\/bitstream\/10665\/255884\/1\/9789241550062-eng.pdf?ua=1."},{"key":"4997_CR43","unstructured":"UNAIDS, WHO, CDC, PEPFAR, FHi360. Global HIV Strategic Information Working Group Survey Guidelines Biobehavioural:For Populations At Risk For HIV 2017."},{"key":"4997_CR44","unstructured":"Bakari M, Mhalu F, Sandstrom E, Pallangyo K. Isoniazid prophylaxis for tuberculosis prevention among HIV infected police officers in Dar Es Salaam. East Africa Med J. 2000;2000:494\u2013497. Available from: https:\/\/www.researchgate.net\/publication\/10660678%0AIsoniazid."},{"key":"4997_CR45","doi-asserted-by":"crossref","unstructured":"Said K, Hella J, Mhalu G, Chiryankubi M, Masika E, Maroa T, et al. Diagnostic delay and associated factors among patients with pulmonary tuberculosis in Dar es Salaam, Tanzania Khadija. Res Artic Infect Dis poverty. 2017; Available from: http:\/\/creativecommons.org\/publicdomain\/.","DOI":"10.1186\/s40249-017-0276-4"},{"key":"4997_CR46","doi-asserted-by":"crossref","unstructured":"Nagu TJ, Aboud S, Matee MI, Maeurer MJ, Fawzi WW, Mugusi F. Effects of isoniazid resistance on TB treatment outcomes under programmatic conditions in a high-TB and -HIV setting: a prospective multicentre study. J Antimicrob Chemother Adv access Publ December 20, 2016 J Antimicrob Chemothe 2016;.","DOI":"10.1093\/jac\/dkw503"},{"key":"4997_CR47","unstructured":"UNAIDS. HIV and AIDS in Tanzania [Internet]. Tanzania; 2019. Available from: www.avert.org."},{"key":"4997_CR48","doi-asserted-by":"crossref","unstructured":"Tadesse Y, Gebre N, Daba S, Gashu Z, Habte D, Hiruy N, et al. Uptake of isoniazid preventive therapy among under-five children: TB contact investigation as an entry point. PLos. 2016;.","DOI":"10.1371\/journal.pone.0155525"},{"key":"4997_CR49","doi-asserted-by":"crossref","unstructured":"Thindwa D, MacPherson P, Choko AT, Khundi M, R Sambakunsi, Ngwira LG, et al. Completion of isoniazid preventive therapy among human immunodeficiency virus positive adults in urban Malawi. Int J Tuberc Lung Dis 2018;22(3):273\u2013279. Available from: http:\/\/dx.doi.org\/10.5588\/ijtld.17.0370%250.","DOI":"10.5588\/ijtld.17.0370"},{"key":"4997_CR50","doi-asserted-by":"crossref","unstructured":"Bourne PA, Eldemire-shearer D, Paul TJ, Lagrenade J, Charles Christopher a. Public and private health care utilization differences between socioeconomic strata in Jamaica Patient Relat Outcome Meas 2010;2010:81\u201391.","DOI":"10.2147\/PROM.S11868"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-020-04997-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-020-04997-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-020-04997-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,9]],"date-time":"2021-04-09T19:08:59Z","timestamp":1617995339000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-020-04997-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,10]]},"references-count":50,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["4997"],"URL":"https:\/\/doi.org\/10.1186\/s12879-020-04997-6","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.2.19464\/v4","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.2.19464\/v1","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.2.19464\/v3","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.2.19464\/v2","asserted-by":"object"}]},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,10]]},"assertion":[{"value":"10 December 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study involved analysis of unlinked data; hence, there was no contact with human subjects. Ethical approval of conducting the study was obtained from the Kilimanjaro Christian Medical University College (KCMuCo RERC#: 2388). Permission to use CTC data was sought from and approved by the MoHCDGEC through the National Aids Control Program (NACP). Patient consent was not required for the analysis of anonymized routine data.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"276"}}